

Donald P Tashkin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5080289/donald-p-tashkin-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

250
papers

15,252
citations

65
h-index

117
g-index

271
ext. papers

17,705
ext. citations

6.5
avg, IF

6.6
L-index

#	Paper	IF	Citations
250	A 4-year trial of tiotropium in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2008 , 359, 1543-54	59.2	1658
249	Cyclophosphamide versus placebo in scleroderma lung disease. <i>New England Journal of Medicine</i> , 2006 , 354, 2655-66	59.2	1125
248	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 708-719	35.1	487
247	Pulmonary hazards of smoking marijuana as compared with tobacco. <i>New England Journal of Medicine</i> , 1988 , 318, 347-51	59.2	375
246	Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. <i>Lancet, The</i> , 2009 , 374, 1171-8 ⁰	40	365
245	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 1026-34	10.2	343
244	A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. <i>Chest</i> , 2013 , 143, 1590-1598 ^{5,3}	5.3	291
243	Gender bias in the diagnosis of COPD. <i>Chest</i> , 2001 , 119, 1691-5	5.3	249
242	The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. <i>The American Review of Respiratory Disease</i> , 1992 , 145, 301-10		228
241	Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 948-55	10.2	209
240	Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. <i>Journal of Immunology</i> , 2000 , 165, 373-80	5.3	187
239	Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. <i>Journal of Neuroimmunology</i> , 2002 , 133, 124-31	3.5	179
238	Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. <i>Chest</i> , 1997 , 112, 319-26	5.3	176
237	Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 1198-205	9.7	165
236	Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. <i>Drugs</i> , 2009 , 69, 549-65	12.1	156
235	Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. <i>Drugs</i> , 2008 , 68, 1975-2000	12.1	156
234	Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1829-34 ⁴		156

233	The role of long-acting bronchodilators in the management of stable COPD. <i>Chest</i> , 2004 , 125, 249-59	5.3	156
232	Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. <i>Lancet, The</i> , 2009 , 374, 712-9	4.0	155
231	Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. <i>Chest</i> , 2011 , 139, 591-599	5.3	151
230	High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. <i>Chest</i> , 2008 , 134, 358-367	5.3	149
229	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine, the</i> , 2017 , 5, 619-626	35.1	148
228	Cardiovascular safety of tiotropium in patients with COPD. <i>Chest</i> , 2010 , 137, 20-30	5.3	148
227	Effects of marijuana smoking on the lung. <i>Annals of the American Thoracic Society</i> , 2013 , 10, 239-47	4.7	144
226	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine, the</i> , 2017 , 5, 956-967	35.1	140
225	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, e4-e27	10.2	137
224	Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2004 , 1, 303-12	2	133
223	Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. <i>Chest</i> , 2003 , 123, 1441-9	5.3	132
222	Acute pulmonary physiologic effects of smoked marijuana and oral (Delta)9 -tetrahydrocannabinol in healthy young men. <i>New England Journal of Medicine</i> , 1973 , 289, 336-41	59.2	122
221	Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2013 , 14, 49	7.3	121
220	Respiratory and immunologic consequences of marijuana smoking. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 715-815	2.9	121
219	Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 91-8	10.2	120
218	Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. <i>Journal of Rheumatology</i> , 2009 , 36, 773-80	4.1	118
217	Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 17-25	2	118
216	Exacerbation frequency and course of COPD. <i>International Journal of COPD</i> , 2012 , 7, 653-61	3	109

215	Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999 , 20, 1286-93	5.7	109
214	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015 , 45, 879-905	13.6	107
213	Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. <i>Chest</i> , 2009 , 136, 1333-1340	5.3	104
212	Cannabis withdrawal among non-treatment-seeking adult cannabis users. <i>American Journal on Addictions</i> , 2006 , 15, 8-14	3.7	102
211	Pulmonary status of habitual cocaine smokers. <i>The American Review of Respiratory Disease</i> , 1992 , 145, 92-100		94
210	Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 32, 566-71	6.1	94
209	Tracheobronchial changes in habitual, heavy smokers of marijuana with and without tobacco. <i>The American Review of Respiratory Disease</i> , 1987 , 136, 142-9		90
208	Subacute effects of heavy marijuana smoking on pulmonary function in healthy men. <i>New England Journal of Medicine</i> , 1976 , 294, 125-9	59.2	90
207	Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. <i>Respiratory Research</i> , 2010 , 11, 149	7.3	89
206	Airway effects of marijuana, cocaine, and other inhaled illicit agents. <i>Current Opinion in Pulmonary Medicine</i> , 2001 , 7, 43-61	3	88
205	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 122-130	2.4	88
204	Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. <i>Journal of Neuroimmunology</i> , 1998 , 83, 133-8	3.5	86
203	Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. <i>Journal of Infectious Diseases</i> , 2002 , 185, 701-5	7	86
202	Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3078-85		85
201	Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2797-808		83
200	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1676-84		82
199	Smoking cessation in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2009 , 103, 963-74	4.6	81
198	Loss of bone density with inhaled triamcinolone in Lung Health Study II. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 1302-9	10.2	78

197	Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001 , 24, 339-44	5.7	76
196	Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. <i>European Radiology</i> , 2011 , 21, 2455-65 ⁸		75
195	Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. <i>Respiratory Medicine</i> , 2008 , 102, 479-87	4.6	75
194	Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018 , 13, 335-349	3	72
193	Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. <i>Chemistry and Physics of Lipids</i> , 2002 , 121, 229-39	3.7	71
192	Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. <i>Respiratory Medicine</i> , 2016 , 117, 198-206	4.6	70
191	An epidemiologic review of marijuana and cancer: an update. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 15-31	4	70
190	Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1301-6	10.2	70
189	Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. <i>Respiration</i> , 1998 , 65, 354-62	3.7	70
188	Differential examination of bronchoalveolar lavage cells in tobacco cigarette and marijuana smokers. <i>The American Review of Respiratory Disease</i> , 1987 , 135, 1271-5		70
187	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1451-1460	9.5	67
186	Respiratory status of seventy-four habitual marijuana smokers. <i>Chest</i> , 1980 , 78, 699-706	5.3	67
185	Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 994-1000	10.2	62
184	Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. <i>Journal of Infectious Diseases</i> , 2003 , 187, 700-4	7	62
183	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 372	5.7	61
182	Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. <i>Thorax</i> , 2018 , 73, 414-421	7.3	60
181	Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension [®] Delivery Technology in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017 , 126, 105-115	4.6	58
180	Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. <i>Respiratory Medicine</i> , 2010 , 104, 1495-504	4.6	58

179	Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003 , 284, L298-306	5.8	58
178	Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. <i>Respiratory Research</i> , 2011 , 12, 6	7.3	57
177	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 374-814	8.14	55
176	A review of nebulized drug delivery in COPD. <i>International Journal of COPD</i> , 2016 , 11, 2585-2596	3	55
175	Respiratory effects of cocaine "freebasing" among habitual users of marijuana with or without tobacco. <i>Chest</i> , 1987 , 92, 638-44	5.3	54
174	Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1641-7	2.4	52
173	Antimicrobial and respiratory burst characteristics of pulmonary alveolar macrophages recovered from smokers of marijuana alone, smokers of tobacco alone, smokers of marijuana and tobacco, and nonsmokers. <i>The American Review of Respiratory Disease</i> , 1991 , 144, 1351-6		51
172	Relative sensitivity and specificity of salivary and serum cotinine in identifying tobacco-smoking status of self-reported nonsmokers and smokers of tobacco and/or marijuana. <i>Archives of Environmental Health</i> , 1989 , 44, 53-8		51
171	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015 , 24, 159-72	9.8	50
170	Small airways in progressive systemic sclerosis (PSS). <i>American Journal of Medicine</i> , 1979 , 66, 201-9	2.4	50
169	Tiotropium HandiHaler in the treatment of COPD: a safety review. <i>International Journal of COPD</i> , 2009 , 4, 397-409	3	49
168	Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 404-15	2	48
167	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 1286-1295	4.7	48
166	Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 644-652	10.2	47
165	Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT [®] trial. <i>Lung</i> , 2011 , 189, 261-8	2.9	46
164	Acute activation of circulating polymorphonuclear neutrophils following in vivo administration of cocaine. A potential etiology for pulmonary injury. <i>Chest</i> , 1997 , 111, 698-705	5.3	45
163	Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 2045-2056	4.7	44
162	Acute effects of inhaled and i.v. cocaine on airway dynamics. <i>Chest</i> , 1996 , 110, 904-10	5.3	44

161	Small airways response to naturalistic cat allergen exposure in subjects with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006 , 118, 1075-81	11.5	44
160	Mechanisms for impaired effector function in alveolar macrophages from marijuana and cocaine smokers. <i>Journal of Neuroimmunology</i> , 2004 , 147, 82-6	3.5	44
159	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2016 , 18, 305	5.7	42
158	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 650-660	10.2	41
157	Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. <i>Current Rheumatology Reports</i> , 2009 , 11, 111-9	4.9	40
156	Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16, 97-105	3	40
155	Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. <i>International Journal of COPD</i> , 2018 , 13, 2587-2601	3	40
154	Smoking Cessation in Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 491-507	3.9	39
153	Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. <i>Respirology</i> , 2011 , 16, 825-35	3.6	39
152	Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT trial. <i>Respiratory Research</i> , 2015 , 16, 65	7.3	38
151	Roflumilast : the new orally active, selective phosphodiesterase-4 inhibitor, for the treatment of COPD. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 85-96	4	37
150	Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. <i>Chest</i> , 2004 , 126, 1123-33	5.3	37
149	Effects of varying marijuana smoking profile on deposition of tar and absorption of CO and delta-9-THC. <i>Pharmacology Biochemistry and Behavior</i> , 1991 , 40, 651-6	3.9	37
148	Minimally important differences in the Mahler [®] Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. <i>Rheumatology</i> , 2009 , 48, 1537-40	3.9	36
147	Efficacy of tiotropium in COPD patients with FEV1 \geq 60% participating in the UPLIFT trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 289-96	2	36
146	Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. <i>Chest</i> , 2017 , 151, 813-820	5.3	35
145	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. <i>Arthritis Care and Research</i> , 2018 , 70, 439-444	4.7	35
144	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2019 , 58, 567-579	3.9	35

143	Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. <i>International Journal of COPD</i> , 2012 , 7, 57-71	3	35
142	Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. <i>Chest</i> , 2012 , 142, 614-621	5.3	35
141	Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome?. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 1571-1579.e10	11.5	35
140	Marijuana and Lung Disease. <i>Chest</i> , 2018 , 154, 653-663	5.3	34
139	Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. <i>Respiratory Medicine</i> , 2017 , 132, 31-41	4.6	33
138	The role of small airway inflammation in asthma. <i>Allergy and Asthma Proceedings</i> , 2002 , 23, 233-42	2.6	32
137	Marijuana smoking, pulmonary function, and lung macrophage oxidant release. <i>Pharmacology Biochemistry and Behavior</i> , 1991 , 40, 663-9	3.9	31
136	Human and rabbit newborn lung macrophages have reduced anti-Candida activity. <i>Pediatric Research</i> , 1988 , 24, 285-90	3.2	31
135	Effect of a single exacerbation on decline in lung function in COPD. <i>Respiratory Medicine</i> , 2017 , 128, 85-91	4.6	30
134	Pulmonary effects of inhaled cannabis smoke. <i>American Journal of Drug and Alcohol Abuse</i> , 2019 , 45, 596-609	3.7	30
133	Impact of changes in regular use of marijuana and/or tobacco on chronic bronchitis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 367-74	2	30
132	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , 2019 , 71, 2059-2067	9.5	29
131	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1367-71	2.4	29
130	Bronchial pathology in chronic marijuana smokers: a light and electron microscopic study. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 33-42	3.6	29
129	Small airways function in nonsmokers with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1984 , 27, 1218-26		29
128	Variations in FEV ₁ decline over time in chronic obstructive pulmonary disease and its implications. <i>Current Opinion in Pulmonary Medicine</i> , 2013 , 19, 116-24	3	28
127	Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. <i>International Journal of COPD</i> , 2015 , 10, 239-59	3	27
126	Marijuana exposure and pulmonary alterations in primates. <i>Pharmacology Biochemistry and Behavior</i> , 1991 , 40, 637-42	3.9	27

125	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. <i>Arthritis Care and Research</i> , 2010 , 62, 1772-8	4.7	26
124	Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. <i>American Journal of Medicine</i> , 2007 , 120, 435-41	2.4	26
123	Acute effects of intravenous cocaine on pulmonary artery pressure and cardiac index in habitual crack smokers. <i>Chest</i> , 1997 , 111, 30-5	5.3	25
122	Serum Bilirubin and Disease Progression in Mild COPD. <i>Chest</i> , 2015 , 148, 169-175	5.3	24
121	Adverse events during the Scleroderma Lung Study. <i>American Journal of Medicine</i> , 2011 , 124, 459-67	2.4	24
120	Defining disease modification in chronic obstructive pulmonary disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 211-25	2	24
119	Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. <i>Quality of Life Research</i> , 2006 , 15, 1383-94	3.7	24
118	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. <i>Respiratory Medicine</i> , 2011 , 105, 1176-88	4.6	23
117	Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 72-83	2.3	22
116	Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. <i>Journal of Asthma</i> , 2014 , 51, 603-9	1.9	22
115	Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?. <i>Current Opinion in Pulmonary Medicine</i> , 2005 , 11, 121-8	3	22
114	Acute and subacute bronchial effects of oral cannabinoids. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 35, 26-32	6.1	22
113	Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. <i>EBioMedicine</i> , 2017 , 19, 139-145	8.8	21
112	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Annals of the American Thoracic Society</i> , 2017 , 4, 121-128	4.7	21
111	Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. <i>International Journal of COPD</i> , 2012 , 7, 73-86	3	21
110	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v27-v32	3.9	20
109	Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV/FVC. <i>Respiratory Medicine</i> , 2019 , 156, 58-68	4.6	20
108	One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. <i>Chest</i> , 2014 , 146, 1531-1542	5.3	20

107	How beneficial is vaping cannabis to respiratory health compared to smoking?. <i>Addiction</i> , 2015 , 110, 1706-7	4.7	20
106	Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011 , 24, 147-52	3.5	20
105	Effects of Crack Cocaine on pulmonary alveolar permeability. <i>Chest</i> , 1997 , 112, 327-35	5.3	20
104	Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. <i>Medical Decision Making</i> , 2008 , 28, 926-37	2.5	20
103	Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. <i>Chest</i> , 2003 , 124, 57-62	5.3	19
102	Peripheral blood lymphocyte subpopulations and mitogen responsiveness in tobacco and marijuana smokers. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 9-14	3.6	19
101	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. <i>Journal of Rheumatology</i> , 2019 , 46, 1316-1325	4.1	18
100	Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. <i>Respiratory Research</i> , 2011 , 12, 129	7.3	18
99	Frequent exacerbations of chronic obstructive pulmonary disease--a distinct phenotype?. <i>New England Journal of Medicine</i> , 2010 , 363, 1183-4	59.2	18
98	The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. <i>American Journal of Medicine</i> , 2006 , 119, 63-72	2.4	18
97	Results of a multicenter study of nebulized inhalant bronchodilator solutions. <i>American Journal of Medicine</i> , 1996 , 100, 62S-69	2.4	18
96	A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. <i>Respiratory Medicine</i> , 2014 , 108, 16-24	4.6	18
95	Premature discontinuation during the UPLIFT study. <i>Respiratory Medicine</i> , 2011 , 105, 1523-30	4.6	17
94	Influence of marijuana potency and amount of cigarette consumed on marijuana smoking pattern. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 43-6	3.6	17
93	The relationship between Helicobacter pylori seropositivity and COPD. <i>Thorax</i> , 2015 , 70, 923-9	7.3	16
92	Implications of Marijuana Decriminalization on the Practice of Pulmonary, Critical Care, and Sleep Medicine. A Report of the American Thoracic Society Marijuana Workgroup. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1700-10	4.7	16
91	Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. <i>American Journal of Medicine</i> , 2007 , 120, S4-13	2.4	16
90	Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>Arthritis Research and Therapy</i> , 2019 , 21, 23	5.7	15

89	Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. <i>Respiratory Medicine</i> , 2013 , 107, 1904-11	4.6	15
88	Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2012 , 13, 66	7.3	14
87	Evidence implicating cocaine as a possible risk factor for HIV infection. <i>Journal of Neuroimmunology</i> , 2004 , 147, 26-7	3.5	14
86	The use of nebulized pharmacotherapies during the COVID-19 pandemic. <i>Therapeutic Advances in Respiratory Disease</i> , 2020 , 14, 1753466620954366	4.9	14
85	Acute Effect of Hookah Smoking on the Human Coronary Microcirculation. <i>American Journal of Cardiology</i> , 2016 , 117, 1747-54	3	14
84	Does smoking marijuana increase the risk of chronic obstructive pulmonary disease?. <i>Cmaj</i> , 2009 , 180, 797-8	3.5	13
83	Impact of habitual cocaine smoking on the physiologic response to maximum exercise. <i>Chest</i> , 1997 , 112, 1008-16	5.3	13
82	Smoked cocaine: patterns of use and pulmonary consequences. <i>Journal of Psychoactive Drugs</i> , 1992 , 24, 265-72	3.6	13
81	Respiratory effects of cocaine freebasing among habitual cocaine users. <i>Journal of Addictive Diseases</i> , 1992 , 11, 59-70	1.7	13
80	Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018 , 5, 46-56	2.7	13
79	Asthma-chronic obstructive pulmonary disease overlap syndrome: What we know and what we need to find out. <i>Annals of Allergy, Asthma and Immunology</i> , 2017 , 118, 241-245	3.2	12
78	Benefit:Risk Profile of Budesonide in Obstructive Airways Disease. <i>Drugs</i> , 2019 , 79, 1757-1775	12.1	12
77	Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. <i>Expert Review of Respiratory Medicine</i> , 2010 , 4, 279-89	3.8	12
76	Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT trial. <i>Respiratory Research</i> , 2018 , 19, 196	7.3	12
75	Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study. <i>Chest</i> , 2019 , 155, 519-527	5.3	11
74	Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy. <i>International Journal of COPD</i> , 2020 , 15, 1225-1243	3	11
73	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. <i>PLoS ONE</i> , 2017 , 12, e0184606	3.7	11
72	Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. <i>Respiratory Research</i> , 2018 , 19, 223	7.3	11

71	Association of sugary beverages with survival among patients with cancers of the upper aerodigestive tract. <i>Cancer Causes and Control</i> , 2016 , 27, 1293-1300	2.8	10
70	Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. <i>Rheumatology (Sunnyvale, Calif)</i> , 2015 , 5,		10
69	Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. <i>International Journal of COPD</i> , 2012 , 7, 43-55	3	10
68	Indacaterol maleate for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2077-85	4	10
67	Imaging of the distal airways. <i>Journal of Allergy and Clinical Immunology</i> , 2009 , 124, S78-83	11.5	10
66	Effects of smoked marijuana of varying potency on ventilatory drive and metabolic rate. <i>The American Review of Respiratory Disease</i> , 1992 , 146, 716-21		10
65	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. <i>Thorax</i> , 2016 , 71, 411-420	7.3	10
64	Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2020 , 72, 316-325	9.5	10
63	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. <i>ACR Open Rheumatology</i> , 2020 , 2, 362-370	3.5	9
62	Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018 , 13, 1873-1888	3	9
61	Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium. <i>International Journal of COPD</i> , 2010 , 5, 41-53	3	9
60	Comparison of bronchial effects of nabilone and terbutaline in healthy and asthmatic subjects. <i>Journal of Clinical Pharmacology</i> , 1983 , 23, 127-33	2.9	9
59	Nebulized Treatments and the Possible Risk of Coronavirus Transmission: Where Is the Evidence??. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020 , 7, 136-138	2.7	9
58	Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers. <i>International Journal of Cancer</i> , 2017 , 140, 2040-2050	7.5	8
57	Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. <i>Respiratory Research</i> , 2014 , 15, 102	7.3	8
56	Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. <i>Lung Cancer</i> , 2014 , 85, 449-56	5.9	7
55	Comparison of the variability of the annual rates of change in FEV ₁ determined from serial measurements of the pre- versus post-bronchodilator FEV ₁ over 5 years in mild to moderate COPD: results of the lung health study. <i>Respiratory Research</i> , 2012 , 13, 70	7.3	7
54	Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. <i>Advances in Therapy</i> , 2009 , 26, 1024-34	4.1	7

53	A 56-year-old woman with COPD and multiple pulmonary nodules. <i>Chest</i> , 2008 , 133, 566-9	5.3	7
52	Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016 , 4, 705-12	5.4	7
51	Determining progression of scleroderma-related interstitial lung disease.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 62-70	2.3	7
50	Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT [®] trial. <i>Respiratory Research</i> , 2016 , 17, 48	7.3	6
49	Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. <i>Respiratory Research</i> , 2019 , 20, 135	7.3	6
48	Chemotaxis of peripheral blood and lung leukocytes obtained from tobacco and marijuana smokers. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 15-20	3.6	6
47	Controversies in Allergy: Is Asthma Chronic Obstructive Pulmonary Disease Overlap a Distinct Syndrome That Changes Treatment and Patient Outcomes?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1142-1147	5.4	6
46	Association of dopamine-related gene alleles, smoking behavior and decline in FEV1 in subjects with COPD: findings from the lung health study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 620-8	2	5
45	Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT [®] Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 122-130	2.7	5
44	Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels. <i>Respiratory Research</i> , 2021 , 22, 142	7.3	5
43	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1005-1013	9.5	5
42	Peripheral Blood Flow Changes to Cutaneous and Muscular Beds in Response to Acute Hookah Smoking. <i>American Journal of Cardiology</i> , 2020 , 125, 1725-1731	3	4
41	Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies. <i>Respiratory Medicine</i> , 2019 , 155, 113-120	4.6	4
40	Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. <i>Respiratory Medicine</i> , 2014 , 108, 1355-62	4.6	4
39	Future of fixed-dose longacting β_2 -agonist and antimuscarinic combination therapy in COPD. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 6-7	35.1	4
38	Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. <i>International Journal of COPD</i> , 2011 , 6, 269-75	3	4
37	Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , 2010 , 4, 703-14	3.8	4
36	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2021 , 48, 1295-1298	4.1	4

35	The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1587-9	4.7	3
34	Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. <i>Respiratory Medicine</i> , 2016 , 120, 91-100	4.6	3
33	Subacute bronchial toxicity induced by an electronic cigarette: take home message. <i>Thorax</i> , 2014 , 69, 588	7.3	3
32	A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. <i>Respiratory Medicine</i> , 2013 , 107, 1912-22	4.6	3
31	Acute and chronic effects of marijuana smoking compared with tobacco smoking on blood carboxyhemoglobin levels. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 27-31	3.6	3
30	Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT [®] Randomized Controlled Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 236-251	2.7	3
29	Smoking cessation in COPD: confronting the challenge. <i>Internal and Emergency Medicine</i> , 2021 , 16, 545-547	5.7	3
28	Tiotropium Respimat [®] Add-on to at Least Ics Therapy Demonstrates Reduced Risk of Severe Asthma Exacerbation and Asthma Worsening in Symptomatic Asthma, Independent of IgE or Blood Eosinophil Levels. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, AB214	11.5	3
27	Once-Daily Tiotropium Respimat [®] Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, AB213	11.5	3
26	Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 161-168	2.2	3
25	Dual anti-inflammatory agents prevent COPD exacerbations. <i>Lancet, The</i> , 2015 , 385, 832-4	4.0	2
24	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 963-967	5.3	2
23	A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. <i>Journal of NeuroImmune Pharmacology</i> , 2018 , 13, 219-229	6.9	2
22	Tiotropium for the treatment of chronic obstructive pulmonary disease. <i>Clinical Practice (London, England)</i> , 2013 , 10, 141-155	3	2
21	Budesonide and risk of pneumonia [AuthorsPreply]. <i>Lancet, The</i> , 2009 , 374, 2051-2052	4.0	2
20	The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device. <i>Pulmonary Medicine</i> , 2021 , 2021, 8881895	5.3	2
19	β-blockers associated with reduced all-cause mortality in COPD. <i>Evidence-Based Medicine</i> , 2012 , 17, 31-2		1
18	Treatment of Interstitial Lung Disease 2012 , 421-427		1

17	Effects of Smoked Marijuana on the Lung and Its Immune Defenses. <i>Journal of Cannabis Therapeutics</i> , 2001 , 1, 87-102		1
16	The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 117-127	2.3	1
15	Marijuana use and pneumonia risk in a cohort of HIV-infected and HIV-uninfected men. <i>Annals of Epidemiology</i> , 2020 , 52, 64-70.e2	6.4	1
14	Dietary glycemic index, glycemic load, and lung cancer risk: A case-control study in Los Angeles County. <i>Cancer Epidemiology</i> , 2020 , 69, 101824	2.8	1
13	Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. <i>International Journal of COPD</i> , 2021 , 16, 945-955	3	1
12	Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II. <i>ACR Open Rheumatology</i> , 2021 , 3, 8-16	3.5	1
11	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. <i>Annals of the American Thoracic Society</i> , 2021 ,	4.7	1
10	A Dose-Ranging Study of Epinephrine Hydrofluoroalkane Metered-Dose Inhaler (Primatene MIST) in Subjects with Intermittent or Mild-to-Moderate Persistent Asthma. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020 , 33, 186-193	3.8	0
9	Impact of marijuana smoking on lung function in older persons. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	0
8	Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2020 , 15, 3105-3122	3	0
7	Efficacy of an inhaled corticosteroid/long-acting β -agonist combination in symptomatic COPD patients in GOLD groups B and D. <i>European Respiratory Journal</i> , 2015 , 46, 255-8	13.6	
6	Advances in Prevention and Treatment of Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 455-6	3.9	
5	What Justifies a Placebo-Controlled Trial of Varenicline for Smoking Cessation in Patients With COPD?: Response. <i>Chest</i> , 2011 , 139, 969-970	5.3	
4	Current Management of Chronic Obstructive Pulmonary Disease. <i>Clinical Pulmonary Medicine</i> , 2005 , 12, S2-S6	0.3	
3	Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2021 , 31, 43	3.2	
2	Mid-expiratory time as a potential spirometric index of early airflow obstruction. <i>Respiratory Medicine</i> , 2021 , 176, 105977	4.6	
1	Long-term safety and efficacy studies of epinephrine HFA metered-dose inhaler (Primatene Mist): a two-stage randomized controlled trial. <i>Journal of Asthma</i> , 2021 , 58, 633-644	1.9	